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Abstract
PURPOSE: There is accumulating evidence that galanin receptors (GALRs) may be tumor suppressors in head and
neck squamous cell carcinoma (HNSCC). Promoter methylation status and gene expression were assessed in a
large panel of primary tumors, based on the hypothesis that CpG hypermethylation might silence the galanin gene.
EXPERIMENTAL DESIGN: Galanin expression was examined using reverse transcription–polymerase chain reaction
(PCR). The methylation status of the galanin promoter was studied using bisulfate sequencing and methylation-
specific PCR. UM-SCC-54 was stably transfected to express galanin. RESULTS: Galanin expression was absent in
3/12 (25.0%) UM-SCC cell lines, whereas three nonmalignant cell lines had stable expression. Galanin methylation
was found in 24/100 (24.0%) cases. HNSCC tumor specimens was significantly correlated with the GALR1 methyl-
ation status (P= 1.88E−06). The presence of galanin promoter hypermethylation was statistically correlated with a
decrease in disease-free survival (log-rank test, P = 6.02E−05). A multivariate logistic regression analysis showed
that methylation of galanin and methylation of the gene pair galanin and GALR1 had an odds ratio for recurrence of
8.95 [95% confidence interval (CI), 2.29–35.03] and 23.84 (95% CI, 2.74–207.17), respectively. UM-SCC-54 cells that
are GALR1-proficient but have hypermethylated galanin exhibited suppressed cell proliferation following exogenous
expression of galanin. CONCLUSIONS: Association of frequent promoter hypermethylation and gene silencing with
poor survival, combined with growth suppression of HNSCC cells after forced gene expression, supports the
hypothesis that galanin acts as a tumor suppressor. These data suggest that galanin and GALR1 are potential
therapeutic targets and prognostic factors.
Translational Oncology (2013) 6, 338–346
Introduction
Head and neck squamous cell carcinoma (HNSCC) is the sixth most
frequent type of cancer and affects ∼500,000 patients per year world-
wide [1]. Various factors are linked to the development ofHNSCC; sex,
tobacco smoking, alcohol consumption, and human papillomavirus
(HPV) infection are major risk factors for the disease [2]. The prognosis
for patients with HNSCC is still poor today despite tremendous tech-
nical advances in surgical treatment, radiotherapy, and chemotherapy.
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The development of novel therapies for treating HNSCC is therefore
urgently required [3]. Current progress in molecular biology should
make it possible to create new strategies for cancer, such as molecular
targeting therapy. Approximately 30% of all pharmaceuticals on the
market today exert their therapeutic effect by interacting with a G protein–
coupled receptor (GPCR) [4]. Several studies have suggested that neuro-
peptides function as tumor suppressor genes and possess potent antitumor
activity in an autocrine and/or paracrine manner [5,6]. Galanin is typi-
cally thought of as a neuropeptide because it widely expressed in the
central and peripheral nervous system and, most abundantly, in the
hypothalamus, where it may serve in the regulation of anterior pituitary
hormones [7–9]. Galanin binding to the extracellular regions of the
GPCRs galanin receptor 1 (GALR1), GALR2, and GALR3 activates
the receptors and stimulates numerous signal transduction and inte-
gration pathways [10,11]. Galanin is involved in the regulation of many
physiological functions, such as feeding, metabolism, and body weight
control [12].
Our studies and those of others support a growth regulatory func-
tion for galanin and its receptors in epithelial cancer [13–15]. Antibody
blockade of GALR1 enhances proliferation of HNSCC cells [13], and
galanin and GALR1 induce a marked and prolonged extracellular
signal-regulated kinase (ERK)1/2 activation, up-regulation of p27Kip1
and p57Kip2, down-regulation of cyclin D1, and consequent inhibition
of cell proliferation [14]. Furthermore, squamous cell cancers and cell
lines that fail to express GALR1 exhibit hypermethylation of CpG
islands in the promoter region of this gene [15].
This study shows the first evidence that loss of galanin ex-
pression is associated with hypermethylation of the promoter re-
gion and that expression can be restored after treatment with the
demethylating agent 5-azacytidine and the histone deacetylase
(HDAC) inhibitor trichostatin A (TSA). Moreover, assessment of
tumor specimens confirmed that hypermethylation is common in
patients’ tumors, with associated GALR1 methylation status and
decreased disease-free survival (DFS). Finally, the restoration of
galanin expression in HNSCC cells resulted in the inhibition of
colony formation in response to galanin stimulation, thereby sup-
porting the hypothesis that this plays a tumor suppressive role
in HNSCC.
Materials and Methods
Tumor Samples and Cell Lines
Tumor specimens were obtained at surgery from 100 primary
HNSCC samples. All patients were treated at the Department of
Otolaryngology, Hamamatsu University School of Medicine. All pa-
tients provided written informed consent under a protocol approved
by the Institutional Review Boards at the Hamamatsu University
School of Medicine. Clinical information including age, sex, tumor
site, smoking status, alcohol exposure, tumor size, lymph node status,
and stage grouping were obtained from the clinical records. The aver-
age age was 63.9 years (range, 39–90), and the male/female ratio was
78:22. The primary tumor was located in the oral cavity (n = 34), the
hypopharynx (n = 24), the larynx (n = 20), the oropharynx (n = 11),
and the paranasal cavity (n = 11). DNA and cDNA from 12 UM-SCC
cell lines were established from patients at the University of Michigan
[16]. The HPV16 E6/E7-transformed oral keratinocyte cell line
HOK16B was a gift from Dr No Hee Park of the University of
California, Los Angeles School of Dentistry [17].
Bisulfite Modification and Methylation-Specific Polymerase
Chain Reaction Analysis
Genomic DNA was extracted using the Wizard Genomic DNA
Purification Kit (Promega, Madison, WI). Bisulfite modification
of genomic DNA was carried out as described earlier [15]. Bisulfite-
treated DNA was polymerase chain reaction (PCR) amplified with
two pairs of methylation-specific PCR (MSP) primers designed for
the promoter region of the galanin gene. The MSP primers for methyl-
ated DNA were MSP-galanin-F (5′-TGA CGC GAT TTC GGG
CGG TT-3′) and MSP-galanin-R (5′-TAT CCG CCG CCC GAT
ATA AC-3′). For unmethylated DNA amplification, the following
unmethylated MSP (UMSP) primers were used: UMSP-galanin-F
(5′-TGA TGT GAT TTT GGG TGG TT-3′) and UMSP-galanin-R
(5′-TAT CCA CCA CCC AAT ATA AC-3′). MSP/UMSP was per-
formed with 25 ng of DNA solution containing 1× PCR buffer, 10× Mg,
10mMdeoxyribonucleotide triphosphate (dNTP), 3%DMSO, 1UFast
Start Polymerase (Roche, Penzberg, Germany), and 10 μM of each
primer for a total volume of 25 μl. The PCR conditions were 94°C
for 5 minutes; 38 cycles at 94°C for 30 seconds, 58.0°C for 30 seconds,
and 72°C for 40 seconds; and a final extension at 72°C for 5 minutes.
The 82-bp PCR products were separated by electrophoresis through
a 9% acrylamide gel, stained with ethidium bromide. Previously de-
scribed primers and conditions were used to analyze the methylation
status of the GALR1 gene [15], p16 gene [18], RASSF1A gene [19],
MGMT gene [20], DAPK gene [20], and DCC gene [21].
Bisulfite Sequencing Analysis for Galanin
Bisulfite-treated DNA was amplified by bisulfite sequencing PCR
with a pair of primers that were specific for modified upper strand
DNA without any CpG sites in their primers. The primer set was
5′-GTT TAT GAT GGT TTA GAG GA-3′ (forward) and 5′-ACC
AAA ACCCTA ACA AAA CC-3′ (reverse). The PCR conditions were
94°C for 5 minutes; 40 cycles at 94°C for 30 seconds, 55.0°C for
30 seconds, and 72°C for 40 seconds; and a final extension at 72°C
for 5 minutes. The PCR products were 430 bp long. Bisulfite se-
quencing analysis was carried out as described previously [15].
RNA Extraction and Quantitative Reverse Transcription–PCR
Total RNA was isolated using the RNeasy Mini Kit (Qiagen,
Hilden, Germany) and treated with RNase-Free DNase (Qiagen). The
cDNA was generated from DNase-treated total RNA using random
primers (Invitrogen, Carlsbad, CA) with SuperScript II Reverse Tran-
scriptase (Invitrogen). Primers were designed as follows: galanin for-
ward, 5′-AAA CGA GGC TGG ACC CTG AAC-3′; galanin reverse,
5′-ATT CTT GTC GCT GAA TGA CCT GTG-3′, GALR1 forward,
5′-TGCACCTTCGTCTTCGGCTAC-3′;GALR1 reverse, 5′-CAC
CAG AAC TGT CTG TGC AGT CTT-3′, GALR2 forward, 5′-CGA
CCT GTG TTT CAT CCT GTG-3′; GALR2 reverse, 5′-GGT AGC
GGA TGG CCA GAT A-3′; GALR3 forward, 5′-CTG ATG CCC
AGA ACA TTT CAC TG-3′; GALR3 reverse, 5′-TGT GCC CAG
CAG GAA GAT TAG G-3′; glyceraldehyde-3-phosphate dehydrogenase
(GAPDH ) forward, 5′-GCA CCG TCA AGG CTG AGA AC-3′;
GAPDH reverse, 5′-TGG TGA AGA CGC CAG TGG A-3′. Quanti-
tative reverse transcription (RT)–PCR was performed with the TaKaRa
Thermal Cycler Dice Real Time System TP800 (TaKaRa, Tokyo,
Japan). For each PCR evaluation, 2 μl of diluted cDNA, 12.5 μl of SYBR
Premix Ex Taq Perfect Real Time (TaKaRa), and 0.5 μl of the primers
were added to a final volume of 25 μl. The thermal cycler conditions
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were one cycle of denaturing at 95°C for 10 seconds, followed by 45 cycles
of denaturing at 95°C for 5 seconds and annealing/extension at 60°C for
30 seconds. Analysis was performedwith Thermal CyclerDice Real Time
System TP800 Software Ver. 1.03A (TaKaRa) following the manufac-
turer’s instructions. The mRNA expression of the target genes was nor-
malized toGAPDHmRNA expression for comparisons between samples.
Reactivation of Galanin Expression
Cultures were incubated either for 48 hours with 5-azacytidine
(15 and 30 μg/ml; Sigma, St Louis, MO), an inhibitor of DNAmethyl-
transferase, for 24 hours with 300 nM TSA (Sigma), an inhibitor of
HDAC, or for 48 hours with 5-azacytidine followed by 24 hours with
TSA. The medium was then removed and cultures were maintained
in standard Dulbecco’s modified Eagle’s medium, which was replaced
every other day [15].
Plasmid Constructs and Growth Suppression Analysis
The UM-SCC-54 cell line, which does not express galanin due to
hypermethylation but does express GALR1, GALR2, and GALR3,
was used in colony-forming assays. Using Lipofectamine Reagent
(Invitrogen), 8 μg of pCMV-SPORT6-preprogalanin mammalian ex-
pression construct or pCMV-SPORT6-empty construct and pTRE-
2hyg (Clontech, Palo Alto, CA) were used to transfect each 6-cm
dish containing 4 × 105 cells seeded 48 hours before transfection. The
cells were maintained in Dulbecco’s modified Eagle’s medium with
hygromycin B (180 μg/ml) (Invitrogen) 48 hours after transfection.
The surviving colonies were counted 14 days later, after staining with
crystal violet (Fisher, Pittsburgh, PA). All experiments were repeated
at least three times. Media from pCMV-SPORT6-preprogalanin and
pCMV-SPORT6-empty–transfected cells were assessed using a galanin
ELISA Kit (Peninsula Labs, San Carlos, CA) according to the manufac-
turer’s directions.
Statistical Analysis
Statistical analyses of the associations between variables were per-
formed by Fisher exact test. Comparisons and tests of the colony for-
mation assay were made by Student’s t test. The disease-free interval
was measured from the date of the treatment to the date when loco-
regional recurrence or distant metastasis was diagnosed. DFS probabil-
ities were estimated by the Kaplan-Meier method, and the log-rank
test was applied to assess the significance of differences among actuarial
survival curves. A multivariate logistic regression analysis was used to
identify the predictive value of the prognostic factors, including the
age, sex, smoking status, alcohol intake, stage grouping, and methylated
genes [22,23]. A significant difference was identified when the prob-
ability was less than .05. The statistical analysis was done with the
StatMate IV software package (ATMS Co, Ltd, Tokyo, Japan).
Results
MSP, Bisulfite Sequencing Analysis, and Quantitative
RT-PCR for Galanin
The guanine and cytosine content in the first 500 bp, including
the first exon and intron, is 79% and is much higher than the overall
guanine and cytosine content of the galanin gene (59%) [24]. Figure 1A
indicates the individual CpG sites as vertical lines and numbered from
1 to 57. CpG sites 1 to 18 are located upstream of the transcription
start site (TSS) and 19 to 57 are located downstream of TSS. A bent
arrow represents the TSS. An arrowhead represents the translation start
site (ATG). The nucleotide sequence of the fragment was used for
methylation analysis. The first exon of galanin is in the untranslated
region (Figure 1A).
Each sample was tested with both sets of primers (MSP and UMSP)
for galanin. These primers were designed on the basis of the bisulfite
sequencing data. The forward primers for MSP and UMSP contained
11 to 14 CpG dinucleotides. The reverse primers for MSP and UMSP
included 24 to 26 CpG dinucleotides. The MSP assay for galanin
correlated with the expression status. All cell lines (UM-SCC-2, UM-
SCC-10B, and UM-SCC-54) with loss of expression showed only
methylated alleles. Cell lines with apparently normal galaninmRNA lev-
els showed only unmethylated alleles (UM-SCC-6, UM-SCC-14B, and
UM-SCC-81B) or both alleles were detected (UM-SCC-1, UM-SCC-
22A, UM-SCC-22B, UM-SCC-23, UM-SCC-56, and UM-SCC-
74B). This study analyzed 12 UM-SCC cell lines for the expression
of galanin by using quantitative RT-PCR and found that 3 of 12
(25.0%) cell lines (UM-SCC-2, UM-SCC-10B, and UM-SCC-54)
had loss of galanin mRNA expression (Figure 1, B and C ).
Sodium bisulfate DNA sequencing was carried out to assess the per-
centage of CpG alleles that are methylated in the galanin 5′ region. The
percentage of methylated alleles for each of the 57 different CpG sites
are shown in Figure 1D for 12 HNSCC cell lines and one control
Figure 1. Diagrammatic representation of the galanin gene and its proximal promoter, galaninmethylation analysis using theMSP assay, the
bisulfite sequencing analysis, and galanin expression by quantitative RT-PCR in HNSCC cell lines. (A) Galanin CpG sites within expanded
views of the promoter region relative to the TSS. The white box encloses the 430-bp region that includes the TSS and the 57 individual
CpG sites that were examined for frequency of methylation. The region analyzed using MSP is shown by the black box (82 bp). The TSS
is represented by a bent arrow. The ATG start codon is represented by an arrowhead. (B) Representative examples of MSP of galanin in
UM-SCC cell lines, showing samples that are fully methylated (UM-SCC-2, UM-SCC-10B, and UM-SCC-54), partially methylated (UM-SCC-1,
UM-SCC-22A, UM-SCC-22B, UM-SCC-23, UM-SCC-56, and UM-SCC-74B), or unmethylated (UM-SCC-6, UM-SCC-14B, and UM-SCC-81B).
(C) The relative mRNA expression as assessed by quantitative RT-PCR of galanin in 12 UM-SCC cell lines. The housekeeping gene GAPDH
was run as a control for RNA integrity. (D) Summary of bisulfite sequencing analysis of galanin in UM-SCC cell lines. The numbers at the
top row indicate the CpG dinucleotide (labeled 1–57) in the amplicon. The cell line number is shown on the left. The next columns show the
rate of methylation of CpG dinucleotides (%) and the number of clones (C) analyzed in each sample. In the column labeled MSP, M(+)
indicates positive for the galanin-methylated form by MSP; M(±) indicates positive for the galanin-methylated and unmethylated form by
MSP; M(−) indicates negative for the galanin-methylated form by MSP. The column labeled RT indicates galanin expression by quantita-
tive RT-PCR: (+), positive expression of galanin; (−), negative expression of galanin; NI, no information. (E) The effect of treatment with
5-azacytidine or TSA or both on galanin expression in three cell lines with densely methylated galanin is shown using quantitative RT-PCR.
The controls were cells treated similarly but without 5-azacytidine or TSA.
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culture, UM-10F fibroblasts. Bisulfite sequencing was used to more
precisely map and determine the density of methylation throughout
the galanin promoter. Bisulfite modification of the cell line’s DNA
and PCR amplification of the galanin promoter region were performed
and at least 11 clones were sequenced for each of the cell lines. Quan-
titative RT-PCR showed that UM-SCC-2, UM-SCC-10B, and UM-
SCC-54 had loss of galanin expression (ΔΔCT value, 3.7E−0.5 + 1.9E
−0.5, 0.0011 + 0.0001, 0.0010 + 0.0004) and had heavy methylation
levels in 57 CpG sites (average, 95.3%, 78.0%, and 71.8%). UM-
SCC-1, UM-SCC-6, UM-SCC-14B, UM-SCC-22A, UM-SCC-22B,
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UM-SCC-23, UM-SCC-56, UM-SCC-74B, and UM-SCC-81B had
stable galanin expression (ΔΔCT value, 0.0205 + 0.0027 to 1.1447 +
0.1479) and moderate or low methylation levels ranging from 0.3%
to 65.5%. The fibroblast cell line UM-10F had a much lower methyl-
ation level (2.3%), in comparison to UM-SCC-10B (78.0%). The con-
cordance between mRNA expression levels and aberrant methylation of
galanin was almost complete (Figure 1, C and D).
Head and neck tumors were examined for galanin methylation,
showing methylated samples (H-3, H-17, H-23, H-33, and H-69)
and unmethylated samples (H-14, H-39, H-52, H-68, and H-96)
(Figure 2A). mRNA was isolated from frozen tissue to determine
whether galaninmethylation in tumor specimens was also associated with
gene silencing. Galanin expression analyzed by quantitative RT-PCR
showed that five tumors, H-3, H-17, H-23, H-33, andH-69 with strong
methylation signals, exhibited little mRNA expression. In contrast,
four of five (H-39, H-52, H-68, and H-96) tumors without galanin
promoter methylation exhibited relatively robust mRNA expression
(Figure 2B).
Galanin Expression after 5-Azacytidine and TSA Treatment
Three cell lines (UM-SCC-2, UM-SCC-10B, and UM-SCC-54)
that showed absence of galanin expression and hypermethylation were
cultured with 5-azacytidine alone, TSA alone, or 5-azacytidine plus
TSA. This facilitated assessing the effect of demethylation induced by
5-azacytidine and an inhibitor of HDAC by TSA. Figure 1E shows that
all three cell lines demonstrated restored galanin expression that corre-
lates in association with demethylation and histone acetylation. The re-
sults show that galanin expression was upregulated after 5-azacytidine
and TSA treatment in comparison to before treatment in the heavily
methylated cell lines.
Quantitative RT-PCR for GALRs and Tumor Suppressor
Activity of Galanin
The expression of GALR1, GALR2, and GALR3 was examined in
UM-SCC-54 and HOK-16B by quantitative RT-PCR. UM-SCC-54
did not express galanin mRNA exhibiting hypermethylation of the
promoter region (Figure 1C ). UM-SCC-54 had stable expression
in GALR1 (ΔΔCT value, 0.2365 + 0.0129), GALR2 (ΔΔCT value,
0.8950 + 0.0299), and GALR3 (ΔΔCT value, 1.5210 + 0.0407;
Figure 3A).
The effect of reexpressing galanin was assessed in the UM-SCC-54
cell line in a colony-forming assay. Wild-type preprogalanin in the
pCMV-SPORT6 construct or empty pCMV-SPORT6 construct were
transfected into the UM-SCC-54 cell line exhibiting galanin hyper-
methylation and loss of galanin expression. Reconstitution of galanin
expression in UM-SCC-54 suppressed relative colony-forming abil-
ity by approximately 65% (P = 7.77E−06; Figure 3B). These results
were consistent through three independent experiments. ELISAs con-
firmed increased concentrations of galanin of 1.96 ± 1.04 ng/ml in
the UM-SCC-54 cells transfected with wild-type preprogalanin in the
pCMV-SPORT6 construct compared to 0.20 ± 0.18 ng/ml in the
empty pCMV-SPORT6 construct–transfected cells.
Clinicopathologic Characteristics
The galanin promoter was methylated in 24 of 100 (24.0%) pre-
viously untreated primary tumors tested with the same primers and
Figure 2. Galanin methylation analysis using the MSP assay and galanin expression by quantitative RT-PCR in HNSCC tumor samples.
(A) Representative examples of MSP of galanin in primary tumors from Hamamatsu University Hospital, showing samples that are meth-
ylated (H-3, H-17, H-23, H-33, and H-69) or unmethylated (H-14, H-39, H-52, H-68, and H-96). (B) Relative galanin mRNA expression as
assessed by quantitative RT-PCR in 10 tumor specimens that were also evaluated for galanin promoter methylation. Specimens H-3, H-17,
H-23, H-33, and H-69 exhibited promoter methylation, but H-14, H-39, H-52, H-68, and H-96 did not.
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unmethylated in 76 (76.0%). The methylation of galanin signifi-
cantly correlated with the GALR1 methylation status (P = 1.88E−06),
p16 methylation status (P = .005), DAPK methylation status (P =
.001), E-cadherinmethylation (P = 1.03E−05), andH-cadherinmethyl-
ation (P = .0002). The presence of galanin promoter methylation was
not associated with any difference in the age of onset, gender, smok-
ing status, tumor site, tumor size, lymph node status, clinical stage,
RASSF1A methylation, MGMT methylation, and DCC methylation
(Table 1).
Prognostic Value of the Galanin and Promoter Methylation
of Other Genes in Head and Neck Primary Tumors
Kaplan-Meier plots indicated that the methylation of galanin in
patients’ tumors was related to the duration of DFS. The presence
of galanin promoter methylation was associated with a statistically
significant decrease in DFS (log-rank test, P = 6.02E−05; Figure 4A).
Patients with a GALR1 methylation status had a significantly re-
duced DFS (log-rank test, P = .004; Figure 4B). Methylation of both
galanin and GALR1 was associated with a DFS rate of 0%, in com-
parison to 58.5% in the absence of methylation of these genes (log-
rank test, P = 4.75E−06; Figure 4C ). Methylation of either galanin
or GALR1 was associated with a DFS rate of 24.4%, in comparison
to 58.5% in the absence of methylation of these genes (log-rank
test, P = .004; Figure 4D). A multivariate logistic regression analysis
showed the estimated odds of recurrence associated with methylation
of galanin and eight other genes. The adjusted odds ratio for recurrence
when galanin was methylated in the primary tumor was 8.95 (95% CI,
2.29 to 35.03; P = .002). Patients with methylation of both galanin and
GALR1 had a significantly higher odds ratio for recurrence of 23.84
(95% CI, 2.74 to 207.17; P = .004) than those without any methyla-
tion of this pair of genes (Figure 5).
Figure 3. Expression of GALRs and growth suppression analysis.
(A) Representative examples of quantitative RT-PCR for the GALR
expression in UM-SCC-54. (B) Relative colony-forming ability for UM-
SCC-54.The vector-transfected number of hygromycin B–resistant
colonies was set at 100%. Colonies larger than 1 mm were counted,
and the results are presented as the means ± SD (bars) of three
separate experiments, each performed in triplicate.
Table 1. Galanin Gene Methylation Status in HNSCC Primary Samples.
Patient and Tumor Characteristics (n = 100) Methylation P Value*
Present (n = 24) Absent (n = 76)
Age
70 and older (29) 7 22
Under 70 (71) 17 54 1
Gender
Male (78) 16 62
Female (22) 8 14 1
Smoking status
Smoker (69) 17 52
Nonsmoker (31) 7 24 1
Alcohol exposure
Ever (58) 10 48
Never (42) 14 28 .096
Tumor size
T1–2 (49) 10 39
T3–4 (51) 14 37 .486
Lymph node status
N0 (44) 7 37
N+ (56) 17 39 .105
Stage
I, II, III (45) 9 36
IV (55) 15 40 .483
Recurrence events
Positive (52) 21 31
Negative (48) 3 45 6.52E−05†
p16 methylation
Yes (54) 19 35
No (46) 5 41 .005†
RASSF1A methylation
Yes (22) 5 17
No (78) 19 59 1
MGMT methylation
Yes (34) 10 24
No (66) 14 52 1
DAPK methylation
Yes (39) 16 23
No (61) 8 53 .002†
E-cadherin methylation
Yes (40) 19 21
No (60) 5 55 1.03E−05†
H-cadherin methylation
Yes (37) 17 20
No (63) 7 56 .0002†
DCC methylation
Yes (58) 16 42
No (42) 8 34 .354
GALR1 methylation
Yes (38) 19 19
No (62) 5 57 1.88E−06†
*Fisher exact probability test.
†P < .05.
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Discussion
Early reports from our group noted that the loss of chromosome 18q
developed with tumor progression and that 18q is also associated with
a significantly decreased survival in HNSCC patients [25,26]. Sub-
sequently, it was shown that tumors with a loss of chromosome 18q23
have alterations in the GALR signaling pathway [27]. The expression
of GALR1 (18q23) mRNA is lost in HNSCC as a consequence of
chromosome loss and DNA methylation [15]. GALR1 induces cell
cycle arrest and GALR2 induces both cell cycle arrest and apoptosis in
HNSCC after galanin treatment [14,28]. Therefore, galanin, GALR1,
and GALR2 might act as tumor suppressors, targets for therapy, and
potential prognostic factors in HNSCC.
Recent advances in molecular biology have made it possible to apply
new strategies, such as gene and molecular targeted therapies for suit-
able cancer treatment. However, in comparison to other lesions such as
breast, renal, and colorectal carcinomas, the application for HNSCC
treatment has been lagging [29]. GPCRs belong to a superfamily of cell
surface signaling proteins that have a pivotal role in many physiological
functions and in multiple diseases, including the development of can-
cer and cancer metastasis [30]. Several studies have suggested that
the neuropeptides function as tumor suppressor genes and possess
potent antitumor activity in human cancers. Hypermethylation of
the tachykinin-1 gene, which encodes the neuropeptides substance P,
neurokinin A, and neuropeptide K and γ, is associated with a poor
prognosis in esophageal squamous cell carcinoma, colon cancer, and
HNSCC patients [5,31,32]. Somatostatin promoter hypermethylation
is a common event in human esophageal adenocarcinoma and colon
cancer [5,32]. The expression and promoter methylation of galanin
is an area that still remains to be explored, despite the accumulated
knowledge in tachykinin-1 and somatostatin. These findings provide
a foundation for further studies on the role of neuropeptide genes in
carcinogenesis and their potential as a biomarker for many types of
tumors. Berger et al. reported that exogenous expression of GalR2
inhibited cell proliferation and induced apoptosis in neuroblastoma
cells [33]. Tofighi et al. showed that galanin induced apoptosis in
GalR2-transfected rat pheochromocytoma cells [34].
This study and previous reports from our group showed the resto-
ration of galanin and GALR1 expression to be induced in HNSCC
cell lines by 5-azacytidine and TSA. Selective drugs that modify spe-
cific epigenetic changes will thus become a crucial part of the thera-
peutic arsenal against cancer in the near future [35]. PI polyamide
conjugates possessing a suberoylanilide hydroxamic acid moiety act as
effective HDAC inhibitors with a broad spectrum of epigenetic activ-
ities [36]. These novel suberoylanilide hydroxamic acid–PI polyamide
conjugates, which were designed to target the promoter region of p16
tumor suppressor gene, induce histone H3 Lys 9 acetylation [37].
Figure 4. Kaplan-Meier estimates of DFS among 100 patients based on their galanin and GALR1methylation status. (A) Galanin: 24 patients
with HNSCC had methylated galanin status (red line), and 76 patients with HNSCC had unmethylated galanin status (blue line); this dif-
ference was statistically significant (P = 6.02E−05). (B) GALR1: 38 patients with HNSCC had methylated GALR1 status (red line), and
62 patients with HNSCC had unmethylated GALR1status (blue line); this difference was statistically significant (P = .004). (C) Galanin and
GALR1: 19 patients with HNSCC hadmethylation of both galanin andGALR1 (MM; red line), and 57 patients with HNSCC had nomethylation
of both galanin and GALR1 (UU; blue line); this difference was statistically significant (P = 4.75E−06). (D) Galanin and GALR1: 43 patients
with HNSCC had methylation of either galanin or GALR1 (M; red line), and 57 patients with HNSCC had no methylation of both galanin and
GALR1 (UU; blue line); this difference was statistically significant (P = .004).
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Epigenetic therapy might be a novel therapeutic strategy for HNSCC
treatment. The establishment of DNA methylation and histone modi-
fication profiles of the primary tumor specimen itself might be a valuable
tool for determining the prognosis and predicting the patient’s response
to therapies.
Galanin expression is frequently absent in HNSCC. The galanin
expression–negative UM-SCC cell lines (3 of 12, 25.0%) are hyper-
methylated in the CpG islands of the galanin promoter region. Fur-
thermore, expression-negative squamous cancers and cell lines exhibit
hypermethylation of CpG islands in the galanin promoter region.
Moreover, galanin expression can be restored after treatment with the
demethylating agent, 5-azacytidine, and the HDAC inhibitor, TSA.
A survey of 100 tumor tissue samples using MSP shows that hyper-
methylation of the galanin promoter is as common as that of genes
frequently thought of as being epigenetically regulated, such as p16
(54%), RASSF1A (22%), MGMT (34%), DAPK (39%), E-cadherin
(40%), H-cadherin (37%), DCC (58%), and GALR1 (38%). Inter-
estingly, there is a significant correlation between galanin promoter
methylation and the GALR1 methylation status in primary tumor
samples. GALR1 methylation was also found in 38 of 100 (38%)
primary tumor specimens. A concurrent analysis showed that both
galanin and GALR1 were completely methylated in 19 (19.0%),
another 24 (24.0%) cases were methylated at either galanin or GALR1,
and 43 (43.0%) cases were methylated at least one of the galanin or
GALR1 promoters. Finally, galanin-GALR1 signaling are frequently
inactivated in HNSCC and this process is associated with tumor de-
velopment. Patients who had hypermethylation of both genes had a
significantly shorter DFS than did patients without methylation of
both genes. A multivariate logistic regression analysis showed that the
methylation of both genes was associated with the most significant odds
ratios of recurrence. Brock et al. reported the methylation of p16
and H-cadherin to be associated with early recurrence of stage I non–
small cell lung cancer [38]. The significant association between galanin
aberrant methylation and promoter hypermethylation of p16 and
H-cadherin, respectively, observed in the current study supports the
usefulness of galanin methylation as a potential molecular marker for
the early recurrence of head and neck lesions. Moreover, exogenous
galanin specifically suppresses colony-forming activity in the GALR1
expressing cell line. The current findings suggested that simultaneous
methylation of the galanin and GALR1 genes occurs in a subset of
HNSCC and may be used as a prognostic marker for patients.
In conclusion, the present study showed that the galanin promoter
methylation profile appears to be an important marker predicting the
clinical outcome of HNSCC. This information can be used to iden-
tify patients with high-risk HNSCC who may benefit from adjuvant
therapy and cautious observation after the resection of primary tumors.
Finally, galanin can be reactivated by altering chromatin modifica-
tions with methyltransferase and HDAC inhibitors, raising the promise
of selective small molecule inhibitors of these enzymes as a potential
therapeutic target for HNSCC.
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